5-Hydroxytryptophan / MDA Cancer Research Results

5-HTP, 5-Hydroxytryptophan: Click to Expand ⟱
Features:
5-HTP (5-Hydroxytryptophan) is a naturally occurring amino acid and chemical precursor in the biosynthesis of serotonin(5-HT).

5-HTP — 5-Hydroxytryptophan (L-5-HTP) is an endogenous amino-acid intermediate in tryptophan metabolism and the immediate biochemical precursor to serotonin (5-HT) and downstream melatonin. It is most commonly used as an orally administered dietary supplement (often derived from Griffonia simplicifolia seed extracts) rather than as a regulated drug product; common abbreviations include 5-HTP and L-5-HTP. In humans it is rapidly converted by aromatic L-amino-acid decarboxylase (AADC/DDC) to serotonin largely in peripheral tissues unless peripheral decarboxylation is pharmacologically inhibited.

Primary mechanisms (ranked):

  1. ↑ Serotonin biosynthesis via AADC/DDC conversion of 5-HTP to 5-HT (rate-limited by peripheral decarboxylation and transport into the CNS)
  2. ↑ Melatonin biosynthesis (indirect) by increasing serotonin substrate availability in pineal pathways (context-dependent)
  3. ↑/↔ Serotonergic GPCR signaling downstream of increased 5-HT tone (5-HT receptor subtype–dependent; includes cAMP/PKA and PLC/IP3/Ca²⁺ axes)
  4. ↔ Platelet and vascular serotonergic tone (serotonin uptake/release; hemostasis/vasoreactivity; context-dependent)
  5. Secondary redox modulation via (a) melatonin’s antioxidant signaling and (b) MAO-dependent 5-HT metabolism generating H₂O₂ (context-dependent)

Bioavailability / PK relevance: Oral PK is variable with prominent peripheral conversion to serotonin; historical human PK work reports multi-hour half-life and non-linear/variable exposure, with substantially altered disposition when co-administered with peripheral decarboxylase inhibitors (e.g., carbidopa) which reduces peripheral conversion and can increase CNS availability.

In-vitro vs systemic exposure relevance: Most mechanistic cellular studies that dose supraphysiologic 5-HTP/5-HT concentrations may exceed achievable free systemic levels with typical supplement dosing; many downstream effects are better interpreted as serotonergic tone (receptor-mediated) rather than direct intracellular target engagement by 5-HTP.

Clinical evidence status: Small-human evidence exists primarily in non-oncology indications (e.g., depression) but is limited by study quality/size; there is no credible clinical anticancer evidence base. Safety constraints and interaction risk (serotonergic drugs) are clinically material and often dominate translation decisions.

5-HTP (AD context) — In Alzheimer’s disease (AD), 5-HTP is mechanistically relevant only indirectly: it can increase serotonin availability (limited by peripheral decarboxylation) and may secondarily influence sleep/circadian biology via serotonin→melatonin pathways. The human evidence for 5-HTP in AD specifically is not established; available clinical work is better described as small studies in older adults (not necessarily AD) assessing cognition/mood, while broader AD-relevant biology is supported mainly by serotonergic-system and melatonin literature rather than 5-HTP intervention trials.

Primary mechanisms (ranked):

  1. ↑/↔ Central serotonergic tone (limited/variable CNS delivery; receptor subtype–dependent)
  2. ↑ Sleep/circadian support via serotonin→melatonin substrate effects (context-dependent)
  3. ↓/↔ Oxidative stress and mitochondrial stress (secondary; largely via melatonin-linked pathways; context-dependent)
  4. ↔ Neuroinflammation and synaptic function (secondary; downstream of serotonergic receptor signaling; context-dependent)
-Serotonin (from 5-HTP) is further converted into melatonin in the pineal gland, regulating sleep-wake cycles
- 5-HTP freely crosses the blood–brain barrier.
-Serotonin Does not cross the blood-brain barrier well if excessively converted in the periphery, which is why it's often taken with carbidopa (a peripheral decarboxylase inhibitor) in clinical contexts.
-Doses over ~300–400 mg/day should be taken cautiously and under supervision.
-Alzheimer’s Disease (AD) patients show marked reductions in serotonin levels and serotonergic neurons, especially in the raphe nuclei and hippocampus. 5-HTP could help restore serotonin levels in the brain, potentially supporting cognition and mood.
-5-HTP may help reduce microglial activation and inflammatory cytokines (e.g. TNF-α, IL-6), both elevated in AD.
-Serotonin and melatonin (a downstream product of 5-HTP) have antioxidant properties, which might help reduce ROS-induced neuronal damage in AD.
-Many AD patients are on SSRIs or cholinesterase inhibitors, which could interact with 5-HTP.

Alzheimer’s-relevant axes for 5-HTP (indirect)

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Central serotonergic function ↑/↔ (delivery-dependent) P/R Potential symptom-domain effects (mood, sleep, behavior) AD biology includes serotonergic-system alterations; 5-HTP’s ability to shift CNS serotonin is variable due to peripheral decarboxylation and competing transport/handling.
2 Sleep–circadian axis ↑/↔ (context-dependent) R/G Sleep consolidation and circadian support Melatonin disruption is common in AD; 5-HTP may increase serotonin substrate for melatonin synthesis in some contexts, but this is indirect and not reliably demonstrated as an AD intervention.
3 Mitochondria and oxidative stress ↓/↔ (secondary) R/G Redox/mitochondrial stress buffering Mechanistic support is stronger for melatonin itself in neurodegeneration than for 5-HTP as a means to raise melatonin in AD.
4 Neuroinflammation and synaptic plasticity ↔ (secondary) G Downstream signaling shifts Serotonergic receptor signaling can modulate inflammatory tone and synaptic function, but directionality is receptor- and circuit-dependent; not a specific 5-HTP signature.
5 Clinical Translation Constraint — — Evidence gap + interaction + quality control No AD-specific efficacy base; serotonergic drug interactions matter in older adults; product quality/impurity concerns have been reported historically in some commercial 5-HTP lots.


MDA, Serum malondialdehyde: Click to Expand ⟱
Source:
Type:
MDA : malondialdehyde. The level of oxidative stress can be measured by assessing the MDA levels.
Since MDA is highly cytotoxic and carcinogenic agent it is frequently used as a biomarker of oxidative stress during major health problems such as cancer, etc.
Malondialdehyde (MDA) is the most widely used agent to estimate the extent of lipid peroxidation. Timely diagnosis of the condition followed by supplementation with antioxidants like beta-carotene, pro-vitamin A, vitamin A, vitamin C, vitamin E, lipoic acid, zinc, selenium, and spirulina can prevent potentially malignant disorders.
MDA is a lipid peroxidation marker
Scientific Papers found: Click to Expand⟱
5296- 5-HTP,    Serotonergic Regulation in Alzheimer’s Disease
- Review, AD, NA
*Risk↓, *5HT↓, *ROS↓, *MDA↓, *Apoptosis↓, *Mood↑, *other↑, *other↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

MDA↓, 1,   ROS↓, 1,  

Cell Death ⓘ

Apoptosis↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 2,  

Synaptic & Neurotransmission ⓘ

5HT↓, 1,  

Functional Outcomes ⓘ

Mood↑, 1,   Risk↓, 1,  
Total Targets: 7

Scientific Paper Hit Count for: MDA, Serum malondialdehyde
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:152  Target#:570  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page